Drugs / PTT-4256
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06634849 | Nov 2024 → Apr 2027 expected | neoplasm | Pathios Therapeutics Pty Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-06-05 | Pathios Therapeutics Pty Ltd | Results Pathios Therapeutics Announces Promising Clinical Progress for First-in-Class GPR65 Antagonist PTT-4256 at ASCO 2026 pathiostherapeutics.com ↗
Even within heavily pre-treated patient cohorts presenting with advanced solid malignancies, Pathios is observing promising early signals of efficacy. |
| 2025-11-11 | Pathios Therapeutics Pty Ltd | Results Pathios Therapeutics Unveils First Public Clinical Data for First-in-Class GPR65 Antagonist PTT-4256 at SITC 2025 pathiostherapeutics.com ↗
Across four escalating dose levels, PTT-4256 was well-tolerated by patients. |
| 2023-04-17 | Pathios Therapeutics Pty Ltd | Results Pathios Unveils PTT-4256, a Potent & Selective Inhibitor of GPR65, in Presentation at AACR 2023 pathiostherapeutics.com ↗
The presentation included the public unveiling of PTT-4256, an internally discovered, oral, highly potent, and selective small molecule inhibitor of GPR65 that has demonstrated excellent drug-like properties and impressive monotherapy anti-tumour activity in preclinical models. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-05 | Pathios Therapeutics Pty Ltd | Pathios Therapeutics Announces Promising Clinical Progress for First-in-Class GPR65 Antagonist PTT-4256 at ASCO 2026 pathiostherapeutics.com ↗ |
| 2025-11-11 | Pathios Therapeutics Pty Ltd | Pathios Therapeutics Unveils First Public Clinical Data for First-in-Class GPR65 Antagonist PTT-4256 at SITC 2025 pathiostherapeutics.com ↗ |
| 2024-11-20 | Pathios Therapeutics Pty Ltd | Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor PTT-4256 in Patients with Advanced Solid Cancers pathiostherapeutics.com ↗ |
| 2023-04-17 | Pathios Therapeutics Pty Ltd | Pathios Unveils PTT-4256, a Potent & Selective Inhibitor of GPR65, in Presentation at AACR 2023 pathiostherapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PTT-4256 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06634849 ↗ |
| Route | Oral | “Oral administration of PTT-4256 tablet with water” NCT06634849 ↗ |